|
Title
|
|
|
|
Persistence of HBsAg-specific antibodies and immune memory two to three decades after hepatitis B vaccination in adults
| |
|
Author
|
|
|
|
| |
|
Abstract
|
|
|
|
| The duration of protection after hepatitis B vaccination is not exactly known. This phase IV study evaluated antibody persistence and immune memory 20-30 years after adult immunization with recombinant hepatitis B vaccine (HBsAg vaccine, Engerix-B) in routine clinical practice. Men and women 40-60 years old, with documented evidence of vaccination with three or four HBsAg vaccine doses 20-30 years earlier and without subsequent booster, were enrolled and received HBsAg vaccine as challenge dose. HBsAg-specific antibodies (anti-HBs) and frequencies of HBsAg-specific circulating memory B cells and CD4(+) T cells expressing combinations of activation markers (CD40L, IL2, IFN gamma, TNF alpha) were measured prechallenge, 7 and 30 days postchallenge. Of 101 participants in the according-to-protocol cohort for immunogenicity, 90.1% had anti-HBs concentrations >= 10 mIU/mL prechallenge administration; 84.2% and 100% mounted an anamnestic response 7 and 30 days postchallenge, respectively. HBsAg-specific memory B and CD4(+) T cells expressing at least two activation markers were low prechallenge and increased markedly postchallenge. These results suggest sustained immune memory and long-term protection 20-30 years after a complete primary HBsAg vaccination course during adulthood, in line with current recommendations that a booster is not needed in fully vaccinated immunocompetent adults. |
| |
|
Language
|
|
|
|
English
| |
|
Source (journal)
|
|
|
|
Journal of viral hepatitis. - Oxford
| |
|
Publication
|
|
|
|
Oxford
:
2019
| |
|
ISSN
|
|
|
|
1352-0504
[print]
1365-2893
[online]
| |
|
DOI
|
|
|
|
10.1111/JVH.13125
| |
|
Volume/pages
|
|
|
|
26
:9
(2019)
, p. 1066-1075
| |
|
ISI
|
|
|
|
000481810100005
| |
|
Pubmed ID
|
|
|
|
31087382
| |
|
Full text (Publisher's DOI)
|
|
|
|
| |
|
Full text (open access)
|
|
|
|
| |
|